Supplementary file 1_Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment.docx

Background<p>The aim of this study was to investigate the mechanism of the Poly ADP-ribose polymerase (PARP) inhibitor pamiparib (PAM) and the tyrosine kinase inhibitor anlotinib (ANL), utilizing a Biological Factor Regulatory Neural Network (BFReg-NN) and metabolomics approach.</p>Metho...

詳細記述

保存先:

書誌詳細
第一著者:	Dong Wang (73290) (author)
その他の著者:	Baiwang Chu (22687046) (author), Tingjie Wen (22687049) (author), Xueyu Wang (1818046) (author), Ying Li (38224) (author), Hanning Chen (1723033) (author), Zhao Zhang (52732) (author), Hua Sun (406210) (author)
出版事項:	2025
主題:	Pharmacology pamiparib anlotinib ovarian cancer cancer stem cell (CSC) untargeted metabolomics artificial intelligence (AI)
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

このレコードへの初めてのコメントを付けませんか!

Supplementary file 1_Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment.docx

類似資料